×

Do you want to link to the external site and leave Amgen.ca?

You are now leaving the Amgen Canada website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.

×

Do you want to link to our other external sites and leave Amgen.ca?

You are now leaving the Amgen Canada website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.

At Amgen, our mission is to serve patients. As a science-based, patient-focused organization, we discover and develop innovative therapies to treat serious illnesses.

Our medicines have made a dramatic difference in the lives of tens of thousands of Canadians. That is the most important measure of our success.

Products

The following table provides the prescribing information for Amgen Canada’s major approved products. Due to differences in global labelling, this information is intended for residents of Canada only.

Canadian regulations limit the amount and scope of information we can provide on our prescription drugs. If you require more information you should consult a qualified health professional.

Interactive dose calculator

Enter sample weight and dose/kg dose in the fields below for an automatic, customized calculation.

(Patient weight x Nplate® dose)
(Patient’s total dose ÷ 500 μg/mL)
Round volume to the nearest hundredth mL

Recommended Initial Dose
The recommended initial dose for Nplate® is 1 µg/kg based on actual body weight, administered once weekly as a subcutaneous injection. All dosing calculations should be based on actual body weight at initiation of treatment.

Dose Adjustments
Use the actual body weight at initiation of therapy, then adjust the weekly dose of Nplate® by increments of 1 µg/kg until the patient achieves a platelet count ≥ 50 x 109/L. Assess the platelet count weekly until a stable platelet count (≥ 50 x 109/L for at least 4 weeks without dose adjustment) has been achieved. Obtain platelet counts monthly thereafter. Do not exceed a maximum weekly dose of 10 µg/kg.

Please consult the Product Monograph for complete dosing and administration information.
PrNplate® is indicated to increase the platelet levels in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP):

  • who are nonsplenectomized and have had an inadequate response or are intolerant to corticosteroids and/or immunoglobulins;
  • who are splenectomized and have had an inadequate response to splenectomy.

Nplate® has been used alone or in combination with other ITP therapies such as corticosteroids, azathioprine, or danazol.

Consult the Product Monograph at http://www.amgen.ca/Nplate_PM.pdf for important information on conditions of clinical use, contraindications, warnings, precautions, adverse reactions, drug interactions and dosing that have not been discussed in this piece. The Product Monograph is also available by calling 1-866-502-6436.

×
  • amgevita
  • aranesp
  • avsola
  • blincyto
  • enbrel
  • evenity
  • kanjinti
  • kyprolis
  • mvasi
  • mvasi
  • neualasta
  • neupogen
  • otezla
  • prolia
  • repatha
  • riabni
  • sensipar
  • vectibix
  • xgeva
×

© 2016-2019 Amgen Inc. All rights reserved.

Privacy Policy Terms of Use